Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures.

Abstract

Oromucosal midazolam (Buccolam™), a benzodiazepine, is approved in the EU for the treatment of paediatric patients (aged 3 months to <18 years) with acute, prolonged, convulsive seizures. In clinical trials in children with prolonged, acute, convulsive seizures, oromucosal midazolam was at least as effective as rectal diazepam and as effective as intravenous diazepam in the treatment of seizures and was generally well tolerated. It has several advantages over rectal diazepam, the previous gold standard of treatment, such as having a more convenient and socially acceptable administration route.

• Authors: Lesley J Scott, Katherine A Lyseng-Williamson, Karly P Garnock-Jones
• Journal: CNS drugs (CNS Drugs) Vol. 26 Issue 10 Pg. 893-7 (Oct 01 2012) ISSN: 1179-1934 [Electronic] New Zealand
• PMID: 22928704 (Publication Type: Journal Article)

Chemical References

• Diazepam
• Midazolam

Topics

• Administration, Buccal
• Adolescent
• Child
• Child, Preschool
• Diazepam (administration & dosage)
• Humans
• Infant
• Midazolam (administration & dosage, adverse effects)
• Seizures (drug therapy)